<p>Revolve Wealth Partners LLC 在最近向证券交易委员会提交的文件中表示，在第三季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股减少了 45.5%。该机构投资者在季度内出售了 12,066 股后，持有 14,461 股该医疗研究公司的股票。Revolve Wealth Partners LLC 在安进的持股在最近一个季度末的价值为 4,081,000 美元。</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他对冲基金和机构投资者也最近调整了对该公司的持股。Fairvoy Private Wealth LLC 在第二季度将其在安进的持股增加了 1.1%。Fairvoy Private Wealth LLC 目前持有 3,171 股该医疗研究公司的股票，价值为 885,000 美元，此前在该期间内又购买了 35 股。Nicholson Wealth Management Group LLC 在第二季度将其在安进的持股增加了 0.6%。Nicholson Wealth Management Group LLC 目前持有 5,918 股该医疗研究公司的股票，价值为 1,652,000 美元，此前在上个季度又购买了 35 股。Crumly &amp; Associates Inc. 在第二季度将其在安进的持股增加了 3.2%。Crumly &amp; Associates Inc. 目前持有 1,146 股该医疗研究公司的股票，价值为 320,000 美元，此前在该期间内又购买了 36 股。Maryland Capital Advisors Inc. 在第二季度将其在安进的持股增加了 5.2%。Maryland Capital Advisors Inc. 目前持有 732 股该医疗研究公司的股票，价值为 204,000 美元，此前在上个季度又购买了 36 股。最后，Lion Street Advisors LLC 在第二季度将其在安进的持股增加了 1.3%。Lion Street Advisors LLC 目前持有 2,773 股该医疗研究公司的股票，价值为 774,000 美元，此前在上个季度又购买了 36 股。对冲基金和其他机构投资者持有该公司 76.50% 的股票。</p>
<h2>内部买卖</h2>
<p>在相关消息中，执行副总裁 Murdo Gordon 于 11 月 12 日星期三出售了 6,879 股该公司的股票。股票以平均价格 336.83 美元出售，总价值为 2,317,053.57 美元。交易完成后，该执行副总裁直接持有公司 41,923 股股票，价值为 14,120,924.09 美元。此次交易使其持股减少了 14.10%。该出售在与证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，资深副总裁 Rachna Khosla 于 11 月 12 日星期三出售了 890 股该股票。股票以平均价格 336.24 美元出售，总价值为 299,253.60 美元。出售后，资深副总裁持有公司 7,082 股股票，价值约为 2,381,251.68 美元。这代表其持股减少了 11.16%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去三个月内共出售了 10,908 股公司股票，价值为 3,674,966 美元。内部人士持有该公司 0.69% 的股票。</p>
<h2>分析师评级变动</h2>
<ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
<p>安进已成为多份研究报告的主题。华尔街 Zen 在 12 月 15 日的报告中将安进的评级从 “买入” 上调至 “强力买入”。Guggenheim 在 11 月 6 日的研究报告中将安进的目标价格从 288.00 美元上调至 305.00 美元，并给予该股票 “中性” 评级。大和资本市场在 11 月 18 日的研究报告中将安进的目标价格从 310.00 美元上调至 370.00 美元，并给予该股票 “跑赢大盘” 评级。高盛集团在 11 月 25 日的研究报告中重申了对安进的 “买入” 评级。最后，斯科舍银行在 11 月 13 日的报告中开始覆盖安进股票。他们给予该股票 “行业跑赢大盘” 评级，目标价格为 385.00 美元。一位分析师对该股票给予了强力买入评级，十位分析师给予了买入评级，十位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，安进目前的平均评级为 “适度买入”，平均目标价格为 332.85 美元。</p>
<p><strong>查看我们对 AMGN 的最新分析</strong></p>
<h2>安进价格表现</h2>
<ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
<p>安进于周二以 331.39 美元开盘。该公司的市值为 1784.5 亿美元，市盈率为 25.61，市盈增长比率为 3.11，贝塔值为 0.45。该股票的 50 日移动平均价格为 320.10 美元，200 日移动平均价格为 300.60 美元。安进的 1 年最低价为 257.05 美元，1 年最高价为 346.38 美元。该公司的债务与股本比率为 5.45，流动比率为 1.28，速动比率为 0.99。</p>
<p>安进（NASDAQ:AMGN - 获取免费报告）最近于 11 月 4 日星期二公布了季度财报。该医疗研究公司报告季度每股收益为 5.64 美元，超出市场共识预期的 5.01 美元，超出幅度为 0.63 美元。该公司季度收入为 95.6 亿美元，而市场共识预期为 89.8 亿美元。安进的净利润率为 19.47%，股本回报率为 162.59%。安进的季度收入同比增长 12.4%。在去年同期，该公司每股收益为 5.58 美元。安进已将其 2025 财年的指导目标设定为 20.600-21.400 美元每股收益。卖方分析师预测安进将在当前财年发布 20.62 美元的每股收益。</p>
<h2>安进增加股息</h2>
<p>该公司最近宣布了季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）的登记投资者将获得每股 2.52 美元的股息。这代表着每年 10.08 美元的年化股息和 3.0% 的股息收益率。这比安进之前的季度股息 2.38 美元有所增加。该股息的除息日为 2 月 13 日（星期五）。安进的派息比率为 73.57%。</p>
<h2>安进简介</h2>
<p>（免费报告）</p>
<p>安进公司（NASDAQ: AMGN）是一家成立于 1980 年，总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、制造和提供针对严重疾病的人类治疗药物。安进的工作重点是基于细胞和分子生物学的生物药物，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
<p>安进的商业产品组合历来包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过安进</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>最后一次黄金牛市</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在安进吗？</h2>
<p>在考虑安进之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而安进并不在名单上。</p>
<p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

安进

<p>Revolve Wealth Partners LLC 在第三季度将其在安进的持股减少了 45.5%，出售了 12,066 股。内部人士最近出售了 10,908 股，价值 367 万美元。分析师的评级不一，普遍认为是适度买入，平均目标价为 332.85 美元。安进的股票开盘价为 331.39 美元，市值为 1784.5 亿美元</p>

<p>Revolve Wealth Partners LLC cut its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 45.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,461 shares of the medical research company's stock after selling 12,066 shares during the quarter. Revolve Wealth Partners LLC's holdings in Amgen were worth $4,081,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Revolve Wealth Partners LLC 在最近向证券交易委员会提交的文件中表示，在第三季度将其在安进公司（NASDAQ:AMGN - 免费报告）的持股减少了 45.5%。该机构投资者在季度内出售了 12,066 股后，持有 14,461 股该医疗研究公司的股票。Revolve Wealth Partners LLC 在安进的持股在最近一个季度末的价值为 4,081,000 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently modified their holdings of the company. Fairvoy Private Wealth LLC lifted its holdings in Amgen by 1.1% in the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock worth $885,000 after buying an additional 35 shares during the period. Nicholson Wealth Management Group LLC raised its position in shares of Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock worth $1,652,000 after acquiring an additional 35 shares in the last quarter. Crumly &amp; Associates Inc. lifted its stake in shares of Amgen by 3.2% in the 2nd quarter. Crumly &amp; Associates Inc. now owns 1,146 shares of the medical research company's stock valued at $320,000 after purchasing an additional 36 shares during the period. Maryland Capital Advisors Inc. boosted its position in shares of Amgen by 5.2% during the second quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company's stock valued at $204,000 after purchasing an additional 36 shares in the last quarter. Finally, Lion Street Advisors LLC boosted its position in shares of Amgen by 1.3% during the second quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company's stock valued at $774,000 after purchasing an additional 36 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者也最近调整了对该公司的持股。Fairvoy Private Wealth LLC 在第二季度将其在安进的持股增加了 1.1%。Fairvoy Private Wealth LLC 目前持有 3,171 股该医疗研究公司的股票，价值为 885,000 美元，此前在该期间内又购买了 35 股。Nicholson Wealth Management Group LLC 在第二季度将其在安进的持股增加了 0.6%。Nicholson Wealth Management Group LLC 目前持有 5,918 股该医疗研究公司的股票，价值为 1,652,000 美元，此前在上个季度又购买了 35 股。Crumly &amp; Associates Inc. 在第二季度将其在安进的持股增加了 3.2%。Crumly &amp; Associates Inc. 目前持有 1,146 股该医疗研究公司的股票，价值为 320,000 美元，此前在该期间内又购买了 36 股。Maryland Capital Advisors Inc. 在第二季度将其在安进的持股增加了 5.2%。Maryland Capital Advisors Inc. 目前持有 732 股该医疗研究公司的股票，价值为 204,000 美元，此前在上个季度又购买了 36 股。最后，Lion Street Advisors LLC 在第二季度将其在安进的持股增加了 1.3%。Lion Street Advisors LLC 目前持有 2,773 股该医疗研究公司的股票，价值为 774,000 美元，此前在上个季度又购买了 36 股。对冲基金和其他机构投资者持有该公司 76.50% 的股票。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, EVP Murdo Gordon sold 6,879 shares of the business's stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 in the last three months. Insiders own 0.69% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Murdo Gordon 于 11 月 12 日星期三出售了 6,879 股该公司的股票。股票以平均价格 336.83 美元出售，总价值为 2,317,053.57 美元。交易完成后，该执行副总裁直接持有公司 41,923 股股票，价值为 14,120,924.09 美元。此次交易使其持股减少了 14.10%。该出售在与证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上找到。此外，资深副总裁 Rachna Khosla 于 11 月 12 日星期三出售了 890 股该股票。股票以平均价格 336.24 美元出售，总价值为 299,253.60 美元。出售后，资深副总裁持有公司 7,082 股股票，价值约为 2,381,251.68 美元。这代表其持股减少了 11.16%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士在过去三个月内共出售了 10,908 股公司股票，价值为 3,674,966 美元。内部人士持有该公司 0.69% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li>
</ul>
<div class="lb-trans"><ul>
<li>5 家医疗公司值得关注，因为行业轮动正在全面展开</li>
</ul>
</div><p>AMGN has been the subject of a number of research reports. Wall Street Zen upgraded Amgen from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Monday, December 15th. Guggenheim upped their target price on shares of Amgen from $288.00 to $305.00 and gave the stock a &#34;neutral&#34; rating in a research report on Thursday, November 6th. Daiwa Capital Markets increased their price target on shares of Amgen from $310.00 to $370.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, November 18th. The Goldman Sachs Group reissued a &#34;buy&#34; rating on shares of Amgen in a research note on Tuesday, November 25th. Finally, Scotiabank initiated coverage on shares of Amgen in a report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $385.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $332.85.</p>
<div class="lb-trans"><p>安进已成为多份研究报告的主题。华尔街 Zen 在 12 月 15 日的报告中将安进的评级从 “买入” 上调至 “强力买入”。Guggenheim 在 11 月 6 日的研究报告中将安进的目标价格从 288.00 美元上调至 305.00 美元，并给予该股票 “中性” 评级。大和资本市场在 11 月 18 日的研究报告中将安进的目标价格从 310.00 美元上调至 370.00 美元，并给予该股票 “跑赢大盘” 评级。高盛集团在 11 月 25 日的研究报告中重申了对安进的 “买入” 评级。最后，斯科舍银行在 11 月 13 日的报告中开始覆盖安进股票。他们给予该股票 “行业跑赢大盘” 评级，目标价格为 385.00 美元。一位分析师对该股票给予了强力买入评级，十位分析师给予了买入评级，十位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，安进目前的平均评级为 “适度买入”，平均目标价格为 332.85 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on AMGN</strong></p>
<div class="lb-trans"><p><strong>查看我们对 AMGN 的最新分析</strong></p>
</div><h2>Amgen Price Performance</h2>
<div class="lb-trans"><h2>安进价格表现</h2>
</div><ul>
<li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>安进股票：在盈利超预期后，新的历史高点即将到来</li>
</ul>
</div><p>AMGN opened at $331.39 on Tuesday. The firm has a market cap of $178.45 billion, a PE ratio of 25.61, a P/E/G ratio of 3.11 and a beta of 0.45. The stock has a 50-day moving average price of $320.10 and a 200-day moving average price of $300.60. Amgen Inc. has a 1 year low of $257.05 and a 1 year high of $346.38. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.</p>
<div class="lb-trans"><p>安进于周二以 331.39 美元开盘。该公司的市值为 1784.5 亿美元，市盈率为 25.61，市盈增长比率为 3.11，贝塔值为 0.45。该股票的 50 日移动平均价格为 320.10 美元，200 日移动平均价格为 300.60 美元。安进的 1 年最低价为 257.05 美元，1 年最高价为 346.38 美元。该公司的债务与股本比率为 5.45，流动比率为 1.28，速动比率为 0.99。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen's revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>安进（NASDAQ:AMGN - 获取免费报告）最近于 11 月 4 日星期二公布了季度财报。该医疗研究公司报告季度每股收益为 5.64 美元，超出市场共识预期的 5.01 美元，超出幅度为 0.63 美元。该公司季度收入为 95.6 亿美元，而市场共识预期为 89.8 亿美元。安进的净利润率为 19.47%，股本回报率为 162.59%。安进的季度收入同比增长 12.4%。在去年同期，该公司每股收益为 5.58 美元。安进已将其 2025 财年的指导目标设定为 20.600-21.400 美元每股收益。卖方分析师预测安进将在当前财年发布 20.62 美元的每股收益。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安进增加股息</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. This is an increase from Amgen's previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen's payout ratio is 73.57%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，将于 3 月 6 日（星期五）支付。2 月 13 日（星期五）的登记投资者将获得每股 2.52 美元的股息。这代表着每年 10.08 美元的年化股息和 3.0% 的股息收益率。这比安进之前的季度股息 2.38 美元有所增加。该股息的除息日为 2 月 13 日（星期五）。安进的派息比率为 73.57%。</p>
</div><h2>Amgen Profile</h2>
<div class="lb-trans"><h2>安进简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.</p>
<div class="lb-trans"><p>安进公司（NASDAQ: AMGN）是一家成立于 1980 年，总部位于加利福尼亚州千橡市的全球生物技术公司。该公司专注于发现、开发、制造和提供针对严重疾病的人类治疗药物。安进的工作重点是基于细胞和分子生物学的生物药物，强调将人类遗传学和蛋白质科学的进展转化为患者的治疗方案。</p>
</div><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p>
<div class="lb-trans"><p>安进的商业产品组合历来包括用于肿瘤学、支持性护理、肾脏病、骨骼健康和心血管疾病的生物制剂。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过安进</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股票” 即将腾飞</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>最后一次黄金牛市</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在安进吗？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑安进之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而安进并不在名单上。</p>
</div><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然安进目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Revolve Wealth Partners LLC 出售了 12,066 股安进公司（Amgen Inc.）的股票